close

OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.04
Volume	(mio) 1.23
Volume Avg	426815
52 Week High	6.38
52 Week Low	0.82
PE	N/A
PE (group average)	39
EPS Year	-1.04
EPS change Q/Q	-90.49%
EPS change Q/Q Yr ago	-86.08%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-96.92%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%